What is the price of Plus Therapeutics (PSTV) today?

A cotação de Plus Therapeutics (PSTV) hoje está em $ 5.84, com uma variação de The stock began the year trading around $ 0.51 and is currently priced at $ 5.84. negociando na casa dos $ 0.51 e hoje está em $ 5.84. Acompanhe o and track broader market trends directly on the platform.

When does Plus Therapeutics (PSTV) pay dividends?

Plus Therapeutics (PSTV) did not pay dividends over the past year.

Is Plus Therapeutics (PSTV) a good investment?

Atualmente, Plus Therapeutics (PSTV) está cotada a $ 5.84, com um P/L de -5.52, This represents a -477% premium compared to its historical average P/E. uma variação de -44.38 em sua cotação e distribuiu $ 0.00 em dividendos, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was -44.38%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Plus Therapeutics (PSTV) stock?

You can buy Plus Therapeutics (PSTV) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol PSTV and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Plus Therapeutics (PSTV) yield today?

Over the past month, Plus Therapeutics (PSTV) has returned -8.61% — -44.38% over the past year, and -99.31% over the past five years, including price appreciation and dividends.Nos últimos 12 meses, a empresa pagou um total de $ 0.00 em dividendos, um Dividend Yield de 0.00%.Se você quisesse comprar 100 ações de Plus Therapeutics (PSTV) hoje, o investimento total seria de $ 584.00, com base na cotação atual de $ 5.84.Based on historical performance, the investment would have grown to approximately:Em 1 ano: $ 324.82Em 5 anos: $ 4.03Em 10 anos: $ 0.00Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

Plus Therapeutics (PSTV): Stock Price, Earnings & Key Metrics

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	103.71	6.69	6.45%	2.31%	$ 542.92 B	21.76%
PFE	52.78	1.57	2.97%	6.90%	$ 141.82 B	18.60%
ABBV	535.81	-56.32	-10.51%	3.20%	$ 372.39 B	4.63%
NVO	26.47	6.33	23.91%	4.17%	$ 198.78 B	50.15%
AZN	91.32	5.94	6.50%	1.76%	$ 281.27 B	20.15%
GILD	79.63	6.87	8.63%	2.46%	$ 160.94 B	29.04%
BMY	43.39	5.78	13.32%	4.39%	$ 116.17 B	23.30%
ZTS	52.11	9.69	18.59%	2.74%	$ 31.32 B	26.57%
REGN	99.86	2.31	2.31%	0.51%	$ 72.62 B	20.17%
HALO	52.78	36.06	68.32%	0.00%	$ 7.92 B	39.83%
AMGN	96.87	19.17	19.79%	2.96%	$ 176.21 B	21.11%
MCK	55.17	-111.26	-201.68%	0.42%	$ 92.79 B	1.75%
HRMY	53.72	1.92	3.57%	0.00%	$ 1.75 B	15.08%
VRTX	107.61	5.73	5.33%	0.00%	$ 110.99 B	34.53%
CAH	114.64	-17.12	-14.93%	1.05%	$ 45.74 B	0.65%
ADMA	43.06	5.00	11.61%	0.00%	$ 1.95 B	39.59%
BIIB	88.77	1.52	1.71%	0.00%	$ 28.36 B	12.89%

Plus Therapeutics Inc. operates in the healthcare sector within the biotechnology industry, focusing on the development of targeted radiopharmaceutical therapies for cancer treatment.

Its main areas of activity include:

• Development of radiopharmaceutical therapies for solid tumors.
• Clinical research and early-stage clinical trials.
• Drug-delivery platforms using radioisotopes.
• Regulatory support and oncology-focused research partnerships.

The company is developing therapies aimed at central nervous system tumors and metastatic cancers, using controlled delivery systems to improve treatment precision and effectiveness.

Industry dynamics affecting the company include regulatory requirements for advanced therapies, high research and development costs, competition in radiopharmaceutical innovation and increasing demand for targeted cancer treatments.

Shares of Plus Therapeutics Inc. trade on the Nasdaq under the ticker PSTV.

History and Development

Plus Therapeutics was founded in 1996 with an initial focus on controlled drug-delivery technologies and targeted therapeutic solutions.

In its early years, the company concentrated on building research capabilities, establishing clinical partnerships and advancing experimental treatment platforms. Growth was driven by expansion into oncology-focused applications and the development of radiopharmaceutical therapies.

Over time, the company broadened its clinical pipeline and strengthened collaborations with medical centers and research institutions. A key milestone occurred in 2019 with a corporate rebranding and strategic shift toward radiopharmaceutical technologies.

In recent years, the company has operated in an environment shaped by advances in precision oncology, regulatory complexity and evolving biotechnology market conditions. It has focused on progressing clinical trials, refining its therapeutic platforms and expanding partnerships, supporting the development of targeted cancer treatments.

PSTV

Plus Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PSTV

review the fundamentals of Plus Therapeutics shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Plus Therapeutics

Plus Therapeutics Inc.

United States

29 years

2000

12

History and Development

Additional Information

PROFIT X PRICE PSTV

Financial Results PSTV

PSTV cash flow

Asset, Revenue and Profit Growth - PSTV

PSTV balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk